This discussion led event will bring together senior Pharma representatives and key academics to discuss current developments in this fast-paced field.Hear key presentations from experts in the field: Vincent Brichard, Senior Vice President, GSK BiologicalsDr Brichard will be presenting on the latest work being carried out at GlaxoSmithKline Biologicals developments in cancer immunotherapeutics and will discuss the latest developments in MAGE-A3 Sonia Quaratino, Senior Medical Director, Merck SeronoThis in-depth review into challenges and advances in cancer immunotherapy from Dr Quaratino of Merck-Serono will explore the most effective delivery techniques and evaluate strategies for positive clinical trial results  Six Key Benefits of Attending: 1.    Develop your understanding of cancer immunotherapeutics from GSK Biologicals, Merck-Serono and Novartis2.    Consider novel strategies to improve success in clinical trials to ensure time and money-efficient vaccine development3.    Evaluate a variety of immunotherapy outcomes and the benefits of developing an immunoscore4.    Discuss effective strategies to overcome the main challenges in particle delivery and the increasing costs of clinical trials5.    Understand the need for these vaccines from the ‘frontline’; hear from the NHS on tumor heterogeneity and concomitant therapies6.    Hear from industry experts on clinical trial data on such candidates such as Stimuvax, CV9102, Intravesical BCG and MAGE-A3